ZNF18 inhibitors are a specialized class of compounds that target and modulate the activity of ZNF18, a zinc finger protein known for its role in gene regulation and transcriptional processes. ZNF18 belongs to the large family of zinc finger proteins, characterized by their ability to bind DNA and influence gene expression through the recognition of specific DNA sequences. The structure of these proteins contains zinc ions that coordinate with cysteine and histidine residues, forming a "finger-like" domain that can interact with nucleic acids. Inhibitors of ZNF18 are designed to disrupt the protein's function, either by blocking its interaction with DNA or by altering its ability to recruit co-factors necessary for transcriptional activity. By influencing this protein's role in gene regulation, these inhibitors play a significant role in understanding the molecular mechanisms behind transcriptional control and cellular regulation.
From a chemical perspective, ZNF18 inhibitors exhibit diverse structural frameworks tailored to target the unique binding sites of the zinc finger domain. The inhibition mechanism can involve direct competition with zinc ions, displacement of the protein from its DNA binding site, or allosteric modulation that alters the protein's conformation. These compounds may incorporate chelating groups to interact with the metal-binding site or possess functional groups that interact with key residues within the DNA-binding interface. In addition, structural specificity is crucial, as these inhibitors must selectively target ZNF18 without broadly affecting other zinc finger proteins that share similar structural motifs. The design and development of ZNF18 inhibitors rely heavily on advanced computational modeling and structural biology techniques to accurately map protein-ligand interactions and optimize their binding affinity and specificity for experimental investigations into gene regulatory mechanisms.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Inhibits a broad spectrum of kinases, possibly leading to reduced phosphorylation of ZNF18. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor that may decrease ZNF18 activity by altering PI3K/AKT signaling pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor that can disrupt pathways involved in the regulation of ZNF18. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor that can suppress protein synthesis, potentially reducing ZNF18 levels. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor that can lead to increased levels of ubiquitinated ZNF18, promoting degradation. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
HDAC inhibitor that can alter gene expression and possibly decrease ZNF18 expression. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
Glycolysis inhibitor that can alter cellular energy states, affecting ZNF18 stability. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
SERCA inhibitor that disrupts calcium homeostasis, potentially affecting ZNF18 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor that can prevent the activation of MAPK/ERK pathway, possibly affecting ZNF18. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor potentially altering transcription factors that regulate ZNF18 expression. |